Quarterly System Demo - Q3 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 September 2026, 09:00 (CEST) to 17 September 2026, 12:30 (CEST)

Submitted by Anonymous (not verified) on 27 January 2026 - 13:30

Quarterly System Demo - Q3 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 September 2026, 09:00 (CEST) to 17 September 2026, 12:30 (CEST)

Quarterly System Demo - Q4 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 10 December 2026, 09:00 (CET) to 10 December 2026, 12:30 (CET)

Submitted by Anonymous (not verified) on 27 January 2026 - 13:30

Quarterly System Demo - Q4 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 10 December 2026, 09:00 (CET) to 10 December 2026, 12:30 (CET)

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 18, Status: Authorised

Submitted by Anonymous (not verified) on 27 January 2026 - 10:30

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 18, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More